Literature DB >> 33519807

The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities.

Fatemeh Bayati1,2, Mahsa Mohammadi3,4, Maryam Valadi1, Saeid Jamshidi2, Arron Munggela Foma1, Ehsan Sharif-Paghaleh1,5.   

Abstract

Regulatory T cells (Tregs) are an immunosuppressive subgroup of CD4+ T cells which are identified by the expression of forkhead box protein P3 (Foxp3). The modulation capacity of these immune cells holds an important role in both transplantation and the development of autoimmune diseases. These cells are the main mediators of self-tolerance and are essential for avoiding excessive immune reactions. Tregs play a key role in the induction of peripheral tolerance that can prevent autoimmunity, by protecting self-reactive lymphocytes from the immune reaction. In contrast to autoimmune responses, tumor cells exploit Tregs in order to prevent immune cell recognition and anti-tumor immune response during the carcinogenesis process. Recently, numerous studies have focused on unraveling the biological functions and principles of Tregs and their primary suppressive mechanisms. Due to the promising and outstanding results, Tregs have been widely investigated as an alternative tool in preventing graft rejection and treating autoimmune diseases. On the other hand, targeting Tregs for the purpose of improving cancer immunotherapy is being intensively evaluated as a desirable and effective method. The purpose of this review is to point out the characteristic function and therapeutic potential of Tregs in regulatory immune mechanisms in transplantation tolerance, autoimmune diseases, cancer therapy, and also to discuss that how the manipulation of these mechanisms may increase the therapeutic options.
Copyright © 2021 Bayati, Mohammadi, Valadi, Jamshidi, Foma and Sharif-Paghaleh.

Entities:  

Keywords:  autoimmune disorders; cancer; clinical trial; induced regulatory T cells; natural regulatory T cells; regulatory T cells; transplantation

Year:  2021        PMID: 33519807      PMCID: PMC7844143          DOI: 10.3389/fimmu.2020.585819

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  248 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

Review 2.  Applications of microarrays to renal transplantation: progress and possibilities.

Authors:  Mei-Sze Chua; Elaine Mansfield; Minnie Sarwal
Journal:  Front Biosci       Date:  2003-09-01

3.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

Review 4.  Revisiting IL-2: Biology and therapeutic prospects.

Authors:  Abul K Abbas; Eleonora Trotta; Dimitre R Simeonov; Alexander Marson; Jeffrey A Bluestone
Journal:  Sci Immunol       Date:  2018-07-06

5.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

6.  TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet.

Authors:  Jack T Lin; Stacey L Martin; Luxi Xia; James D Gorham
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

Review 7.  Targeting Treg cells in cancer immunotherapy.

Authors:  Atsushi Tanaka; Shimon Sakaguchi
Journal:  Eur J Immunol       Date:  2019-07-05       Impact factor: 5.532

8.  Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells.

Authors:  C Blaser; M Kaufmann; C Müller; C Zimmermann; V Wells; L Mallucci; H Pircher
Journal:  Eur J Immunol       Date:  1998-08       Impact factor: 5.532

9.  Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells.

Authors:  Balraj Singh; Kendra R Cook; Laura Vincent; Carol S Hall; Jacob A Berry; Asha S Multani; Anthony Lucci
Journal:  J Surg Res       Date:  2008-03-18       Impact factor: 2.192

10.  Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action.

Authors:  B M Hall; N W Pearce; K E Gurley; S E Dorsch
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.

Authors:  Felix Sebastian Nettersheim; Felix Simon Ruben Picard; Friedrich Felix Hoyer; Holger Winkels
Journal:  Front Cardiovasc Med       Date:  2022-01-13

2.  Identifying Potential Diagnostic Genes for Diabetic Nephropathy Based on Hypoxia and Immune Status.

Authors:  Changyan Li; Feng Su; Le Zhang; Fang Liu; Wenxing Fan; Zhen Li; JingYuan Ma
Journal:  J Inflamm Res       Date:  2021-12-14

Review 3.  Small Extracellular Vesicles in Transplant Rejection.

Authors:  Justyna E Gołębiewska; Anna Wardowska; Monika Pietrowska; Anna Wojakowska; Alicja Dębska-Ślizień
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 4.  The Cellular and Molecular Immunotherapy in Prostate Cancer.

Authors:  Anirban Goutam Mukherjee; Uddesh Ramesh Wanjari; D S Prabakaran; Raja Ganesan; Kaviyarasi Renu; Abhijit Dey; Balachandar Vellingiri; Sabariswaran Kandasamy; Thiyagarajan Ramesh; Abilash Valsala Gopalakrishnan
Journal:  Vaccines (Basel)       Date:  2022-08-22

Review 5.  Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment.

Authors:  Bayley R McRitchie; Billur Akkaya
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.